Log in

NASDAQ:EVOK - Evoke Pharma Stock Price, Forecast & News

$1.48
+0.03 (+2.07 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$1.43
Now: $1.48
$1.54
50-Day Range
$1.39
MA: $1.50
$1.62
52-Week Range
$0.50
Now: $1.48
$3.26
Volume78,865 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:EVOK
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.


Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) posted its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.02. View Evoke Pharma's Earnings History.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Evoke Pharma.

What price target have analysts set for EVOK?

2 Wall Street analysts have issued twelve-month price targets for Evoke Pharma's shares. Their forecasts range from $1.33 to $5.00. On average, they expect Evoke Pharma's stock price to reach $3.17 in the next year. This suggests a possible upside of 113.9% from the stock's current price. View Analyst Price Targets for Evoke Pharma.

What is the consensus analysts' recommendation for Evoke Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evoke Pharma.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (1/4/2020)
  • 2. HC Wainwright analysts commented, "Valuation methodology and risks. We remain in a holding pattern until further clarity is obtained regarding the issues raised in the CRL and the degree to which they can be addressed near-term, as well as the timeline to potential resubmission of the Gimoti NDA and possible regulatory approval of the drug." (8/9/2019)

Has Evoke Pharma been receiving favorable news coverage?

Media headlines about EVOK stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evoke Pharma earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Evoke Pharma.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a decrease in short interest in January. As of January 15th, there was short interest totalling 534,100 shares, a decrease of 25.3% from the December 31st total of 715,000 shares. Based on an average daily volume of 255,800 shares, the days-to-cover ratio is currently 2.1 days. Currently, 2.5% of the company's shares are short sold. View Evoke Pharma's Current Options Chain.

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.18%). View Institutional Ownership Trends for Evoke Pharma.

Which major investors are buying Evoke Pharma stock?

EVOK stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Evoke Pharma.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $1.48.


MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  571
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel